A2T.F ATRYS HEALTH S.A. EO-01
- Market cap
- EUR 193M
- P/E
- -
- P/B
- 1.28x
- ROE
- -66.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is A2T.F undervalued?
Graham numberThe Graham number of ATRYS HEALTH S.A. EO-01 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ATRYS HEALTH S.A. EO-01 fundamental analysis
No fundamental analysis for ATRYS HEALTH S.A. EO-01 yet.
ATRYS HEALTH S.A. EO-01 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ATRYS HEALTH S.A. EO-01
Atrys Health, S.A., together with its subsidiaries, provides diagnostic services and medical treatments in Spain, Portugal, and Latin America. It operates through three segments: Diagnosis, Oncology, and Preventive Medicine. The company offers integrated diagnostics services comprising structural and molecular pathology, genetics, and nuclear medicine diagnosis; telediagnosis activities in the fields of radiology and cardiology; oncology treatment services, such as chemother…
Full company profileATRYS HEALTH S.A. EO-01 financial statements
ATRYS HEALTH S.A. EO-01 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 121M | 158M | 202M | 130M | 141M |
| Gross Profit | 101M | 126M | 142M | 65.5M | 61.3M |
| Operating Income | -12.4M | -3.57M | 3.01M | 5.86M | -5.74M |
| EBITDA | - | 13.7M | 29.0M | 17.0M | -9.96M |
| Net Income | -23.3M | -23.1M | -45.6M | -31.8M | -100M |
| EPS | -0.38 | -0.30 | -0.60 | -0.42 | -1.32 |
| Balance Sheet | |||||
| Total Assets | 564M | 704M | 629M | 584M | 494M |
| Total Liabilities | 292M | 368M | 339M | 331M | 342M |
| Shareholders' Equity | 273M | 336M | 290M | 253M | 152M |
| Cash & Short-term Investments | 35.1M | 34.3M | 41.8M | 20.4M | 13.1M |
| Cash Flow | |||||
| Operating Cash Flow | 4.69M | -15.4M | 5.70M | 3.00M | -1.56M |
| Capital Expenditure | 8.57M | 15.2M | 13.1M | 13.1M | 12.5M |
| Free Cash Flow | -3.87M | -30.6M | -7.45M | -10.1M | -14.1M |
| Ratios | |||||
| ROE | -8.5% | -6.9% | -15.7% | -12.6% | -66.0% |
| ROA | -4.1% | -3.3% | -7.2% | -5.4% | -20.3% |
| Net Profit Margin | -19.2% | -14.6% | -22.6% | -24.4% | -71.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ATRYS HEALTH S.A. EO-01 dividends
ATRYS HEALTH S.A. EO-01 has not paid dividends in the last 5 fiscal years.
Who owns ATRYS HEALTH S.A. EO-01
- Insiders 56.77%
- Institutions 11.07%
- Public & others 32.16%
- Shares outstanding 75.9M
- Free float 42.5M
ATRYS HEALTH S.A. EO-01 company profile
- Company name
- ATRYS HEALTH S.A. EO-01
- Ticker
- A2T.F
- ISIN
- ES0105148003
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 763
- Fiscal year end
- December
- Address
- Calle Velázquez, number 157, Madrid, Spain, 28002
- Phone
- 34 917 819 465
- Website
- atryshealth.com
About ATRYS HEALTH S.A. EO-01
Atrys Health, S.A., together with its subsidiaries, provides diagnostic services and medical treatments in Spain, Portugal, and Latin America. It operates through three segments: Diagnosis, Oncology, and Preventive Medicine. The company offers integrated diagnostics services comprising structural and molecular pathology, genetics, and nuclear medicine diagnosis; telediagnosis activities in the fields of radiology and cardiology; oncology treatment services, such as chemotherapy, immunotherapy, radiotherapy, and brachytherapy; second opinion and genetic counselling; and diagnostic reports and genetic tests. It also provides telemedicine services, such as teleradiology, telecardiology, teleoncology, teledermatology, teleophthalmology, and teleconsultations; prevention plans for companies, which includes training plans on occupational risk prevention; Smart Data, a technological database for healthcare; and research and development services. The company was formerly known as Althia Health, S.L. and changed its name to Atrys Health, S.A. in May 2016. Atrys Health, S.A. was incorporated in 2007 and is headquartered in Madrid, Spain.
ATRYS HEALTH S.A. EO-01 management
9- Dr. Carlos Cordon-CardoFounder & Scientific Vice President
- Dr. Zvi FuchsFounder and Medical Vice President
- Alberto IriondoChief Financial Officer
- Luis DuranGlobal Chief Technology Officer
- Ms. Gabriela Camunas CaruanaGeneral Counsel
- Roberto LapiezaSales Director
- Helena BorràsChief People Officer
- Ms. María Rosa González SansManaging Director of Prevention
- Mr. Alberto Castaneda GonzalezSecretary